Abstract. Models of long-term estrogen-deprived breast cancer cells are utilized in the laboratory to mimic clinical aromatase inhibitor-resistant breast cancer and serve as a tool to discover new therapeutic strategies. The MCF-7:5C and MCF-7:2A subclones were generated through long-term estrogen deprivation of estrogen receptor (ER)-positive MCF-7 cells, and represent anti-hormone-resistant breast cancer.
Introduction
Aromatase inhibitor-resistant breast cancer cells are modeled in vitro by long-term E 2 -deprived breast cancer cell lines. The MCF-7:WS8 cell line represents a clone of the estrogen receptor (ER)-positive cell line MCF-7 that is highly sensitive to E 2 -stimulated growth (1) . The MCF-7:5C and MCF-7:2A subclones are derived from the parental MCF-7 cell line through long-term E 2 deprivation (1-4). MCF-7:5C cells express wild-type ER at a higher level than the parental line, and are progesterone receptor (PR)-negative (3) . These cells grow in the absence of E 2 , and do not respond to 4-hydroxytamoxifen (4-OHT) (2, 3) . MCF-7:2A cells can induce expression of PR and express both wild-type (66 kDa) and mutant (77 kDa) ER (4, 5) . The mutant ER contains a repeat of exons 6 and 7 and cannot bind E 2 nor anti-estrogens; it is expressed 4-to 10-fold lower than the wild-type ER (6) . The total ER level of MCF-7:2A cells is higher than in parental MCF-7 cells, and they also grow in E 2 -free media. 4-OHT and pure anti-E 2 are able to block their growth (4, 5) .
In addition to the different responses to anti-E 2 observed in MCF-7:5C versus MCF-7:2A cells, they also have different apoptotic responses to E 2 . The MCF-7:5C cells undergo apoptosis and die during the first week of E 2 treatment, whereas the MCF-7:2A cells die later, after two weeks of E 2 treatment (7). MCF-7:5C cell response to estrogens and anti-estrogens has been extensively studied in our lab; the data show that these cells undergo E 2 -induced apoptosis through mechanisms associated with endoplasmic reticulum stress (ERS) and oxidative stress (8, 9) . Thus far, there has been less focus on the classification and mechanisms of the MCF-7:2A response.
Network enrichment analyses done using gene arrays in timecourse experiments show overexpression of apoptotic-and stress-related pathways in the MCF-7:5C cells after 24-96 h of E 2 treatment; however, these analyses show the MCF-7:2A cells expressing more genes associated with glutathione metabolism during this time period of E 2 exposure (Fig. 1 ). This suggests that the two cell lines respond to E 2 treatment using different signaling pathways. The MCF-7:5C cells respond by quickly inducing apoptosis, while the antioxidant pathway may be more relevant to the MCF-7:2A cells. Experiments were designed to interrogate the apoptotic, stress and antioxidant pathways in both cell lines to distinguish signaling mechanisms in response to E 2 .
The concept of E 2 -induced death is important because of its clinical relevance. A clinical study published in 2009 (10) compared two doses of E 2 for second-line treatment after breast cancer patients had failed aromatase inhibitor therapy. The authors showed that after long-term anti-hormone therapy, no response is lost with the lower dose of E 2 ; overall Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells about 30% of women responded to E 2 treatment. The goal of this study is to uncover the mechanisms preventing the other 70% of patients from responding, and perhaps find ways to circumvent their resistance. To this end, MCF-7:2A cells were used as a model for E 2 -deprived breast tumors with the ability to evade E 2 -induced apoptosis in the clinic.
Materials and methods
Cell culture. All cell lines were cultured in phenol red-free RPMI-1640 media supplemented with 10% charcoal-stripped fetal bovine serum (SFS). Media and treatments were replaced every three days. Estradiol (E 2 ) (Sigma-Aldrich, St. Louis, MO, USA), buthionine sulfoximine (BSO) (Sigma-Aldrich), and combinations were dissolved in ethanol and then in media. AG1024 (Calbiochem, San Diego, CA, USA) was dissolved in DMSO and then in media.
DNA assays. MCF-7:WS8, MCF-7:5C and MCF-7:2A cells were harvested after 7 or 14 days treatment with vehicle (0.1% ethanol), E 2 (10 -9 mol/l, 1 nM), BSO (10 -4 mol/l, 100 µM), or E 2 (1 nM) + BSO (100 µM). DNA content was measured as previously described (11) .
Western blot analysis. Total MAPK (#9102), phosphorylated MAPK (#9101), total AKT (#9272), phosphorylated AKT (#4051L), total eIF2α (#9722S), phosphorylated eIF2α (#9721S), and IRE1α (#3294S) antibodies were all purchased from Cell Signaling Technology (Beverly, MA, USA). IGF-1Rβ antibody (sc-713) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). β-actin loading control antibody (A5441) was purchased from Sigma-Aldrich. Proteins were harvested from cells using cell lysis buffer (Cell Signaling Technology) supplemented with Protease Inhibitor Cocktail Set I and Phosphatase Inhibitor Cocktail Set II (Calbiochem). Bicinchoninic acid (BCA) assay was used to quantify total protein content (Rio-Rad Laboratories, Hercules, CA, USA). Protein (50 µg) was probed and visualized as previously described (11) .
Cell cycle analysis. MCF-7:2A cells were cultured in dishes and treated with vehicle (0.1% ethanol) or E 2 (10 -9 mol/l, 1 nM). Cells were harvested after 24 h, fixed in 75% ethanol on ice, stained with propidium iodide and sorted using FACS flow cytometry (Becton Dickinson, San Jose, CA, USA). Results were analyzed using CellQuest software.
RT-PCR. Cells were harvested using TRIzol, and RNA was isolated using RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA was reverse transcribed to cDNA using a kit (Applied Biosystems, Foster City, CA). SYBR-Green (Applied Biosystems) was used for quantitative real-time polymerase chain reaction (RT-PCR) in a 7900HT Fast Real-Time PCR system (Applied Biosystems).
Glutathione assay. Cells were harvested and de-proteinized with 5% 5-sulfosalicylic acid solution (SSA) (Sigma-Aldrich). Total glutathione [reduced glutathione (GSH) plus glutathione disulfide (GSSG)] was measured spectroscopically at 412 nm using a Glutathione Assay Kit (CS0260, Sigma-Aldrich) and the manufacturer's instructions.
ROS assay. MCF-7:2A cells were harvested, stained with 10 -6 mol/l (1 µM) CM-H2DCFDA (Invitrogen, Eugene, OR, USA), and analyzed for ROS fluorescence using flow cytometry.
Statistical analysis.
Values reported are means ± standard deviation (SD). Significant differences were found by Student's t-test. P-values <0.05 were considered to indicate a statistically significant difference.
Results

MCF-7:
2A initial response to E 2 . The MCF-7:WS8, MCF-7:5C and MCF-7:2A cell lines respond differently to 10 -9 mol/l (1 nM) E 2 . In the presence of 1 nM E 2 , MCF-7:WS8 cells are stimulated to proliferate over 7 days, whereas MCF-7:5C cells are killed by this time point ( Fig. 2A) . MCF-7:2A cell growth is unaffected by the presence of E 2 after one week, but their DNA is reduced by 50% after the second week of treatment ( Fig. 2A) . Interestingly, MCF-7:2A cells are initially stimulated to proliferate in response to E 2 . After 24 h-treatment with 1 nM E 2 , both the mitogen-activated protein kinase (MAPK) and serine/threonine protein kinase Akt (AKT) pathways are activated, as shown by an increase in phosphorylated MAPK (p-MAPK) and phosphorylated AKT (p-AKT) proteins, respectively (Fig. 2B) . Further, MCF-7:2A cells treated with E 2 for 24 h show an increase in the percentage of dividing cells compared with vehicle treatment (34.78 versus 20.17%), illustrated by S-phase in cell cycle analysis (Fig. 2C ).
MCF-7:5C and MCF-7:2A UPR.
To determine whether the different biological effects observed in MCF-7:5C and MCF-7:2A cells is due to different patterns of the unfolded protein response (UPR), proteins associated with the UPR were measured over a 72 h timecourse. Two markers of the UPR, phosphorylated eIF2α (p-eIF2α) and IRE1α, were visualized by western blot analysis in MCF-7:5C and MCF-7:2A cells in the presence of vehicle and 1 nM E 2 ( Fig. 3) . p-eIF2α is directly downstream of protein kinase RNA-like endoplasmic reticulum kinase (PERK), a sensor which initiates UPR. Both cell lines show an increase in the protein expression of p-eIF2α and IRE1α by 72 h of E 2 treatment, indicating activated UPR. Though MCF-7:2A cells show a slightly higher basal p-eIF2α level, no differences in UPR activation can be seen between the two cell lines.
MCF-7:5C and MCF-7:2A estrogen-induced apoptosis.
To determine whether MCF-7:2A cells experience apoptosis through the same mechanism as MCF-7:5C cells, RT-PCR was used to quantify mRNA levels of apoptosis-related genes. MCF-7:5C cells noticeably upregulate LTA (4.19±1.92 fold change), LTB (5.39±1.82), TNFα (9.40±3.86), and BCL2L11 (6.06±0.87) after 72 h of E 2 treatment, while MCF-7:2A cells show no major changes during this time period (Fig. 4A) . MCF-7:2A cells were then treated with E 2 for a longer time period to measure apoptosis-related genes during the time when they appear to die. MCF-7:2A cells increase both TNFα (33.55±12.09 fold change) and BCL2L11 (3.71±0.35 fold change) after 12 days of 1 nM E 2 treatment (Fig. 4B) . The upregulated apoptosis-related genes correspond to the time when cell death is most apparent in both cell lines, during week one in MCF-7:5C cells, and during week two in MCF-7:2A cells.
MCF-7:5C and MCF-7:
2A oxidative stress. Heme oxygenase 1 (HMOX1) was used as an indicator to illustrate when MCF-7:5C and MCF-7:2A cells experience oxidative stress. After 72 h of 1 nM E 2 treatment, HMOX1 mRNA was increased 4.61-fold in MCF-7:5C cells (Fig. 5A ), suggesting this cell line undergoes oxidative stress at this time point. MCF-7:2A cells did not generate an upregulation of HMOX1 mRNA until 12 days of 1 nM E 2 treatment when it increased 10.03-fold (Fig. 5B) , suggesting an earlier protective mechanism inherent in these cells to prevent oxidative stress longer than MCF-7:5C cells.
Glutathione is a potent antioxidant and was quantified in MCF-7:5C and MCF-7:2A cells to illustrate a potential protective mechanism in MCF-7:2A cells against oxidative stress (Fig. 6A) . In fact, MCF-7:2A cells have significantly more basal glutathione than do MCF-7:WS8 and MCF-7:5C cells (Fig. 6A) . Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks glutathione synthesis by inhibiting γ-glutamylcysteine synthetase. BSO (100 µM) dramatically decreases glutathione levels in both MCF-7:5C and MCF-7:2A cells (Fig. 6B) . To ask the question of whether glutathione is protecting MCF-7:2A cells from oxidative stress and E 2 -induced apoptosis, HMOX1 was measured following treatment with vehicle, 1 nM E 2 alone, 100 µM BSO alone, and 1 nM E 2 + 100 µM BSO after 24, 48 and 72 h (Fig. 6C) . MCF-7:2A cells show increased HMOX1 mRNA at 72 h after treatment with 100 µM BSO and 1 nM E 2 + 100 µM BSO (3.57±0.36 and 2.60±0.70 fold change, respectively), suggesting a protective role of glutathione in these cells. Reactive oxygen species (ROS) increased 634% over vehicle in MCF-7:2A cells after 12 days of the combination treatment (Fig. 6D) . Furthermore, 1 nM E 2 + 100 µM BSO treatment caused a significant decrease in DNA after 14 days treatment (Fig. 6E) , suggesting that oxidative stress is a key factor in determining E 2 -induced MCF-7:2A cell death.
MCF-7:
5C and MCF-7:2A IGFR. Insulin-like growth factor receptor β (IGF-1Rβ) upregulation is another mechanism (Fig. 7A) . This is consistent at the protein level as shown by western blot analysis, where MCF-7:2A cells exhibit more IGF-1Rβ protein expression than MCF-7:5C cells (Fig. 7B) . When treated with an IGF-1Rβ inhibitor (10 µM AG1024) for 7 days, MCF-7:2A cells show significantly decreased DNA content when compared to vehicle and 1 nM E 2 treatments (Fig. 7C ). Combination treatment of 1 nM E 2 + 10 µM AG1024 decreased DNA content significantly more than either treatment alone (Fig. 7C) , suggesting an integral role of IGF-1Rβ in MCF-7:2A cells evading E 2 -induced apoptosis. To interrogate this further, growth pathway proteins were measured in response to 10 µM AG1024 treatment. MAPK and AKT pathways are both blocked by the IGF-1Rβ inhibitor after 72 h as shown by decreased p-MAPK and p-AKT levels when compared to vehicle-treated MCF-7:2A cells (Fig. 7D) .
Discussion
This study investigated the mechanisms through which MCF-7:2A cells evade E 2 -induced apoptosis in vitro as a means to understand resistant breast cancer cells after long-term anti-hormone therapy in the clinic. After failure on an aromatase inhibitor, approximately 30% of breast cancer patients will respond to treatment with E 2 (10); their nascent or remaining breast tumors will become cytostatic or disappear with physiological levels of E 2 . Further, E 2 replacement therapy (ERT) has been shown to reduce the risk of breast cancer in hysterectomized post-menopausal women (12) , perhaps due to E 2 -deprived breast cancer cells undergoing E 2 -induced apoptosis before resulting in clinically apparent disease. This study sought to discriminate between E 2 -deprived breast tumors that will quickly respond to treatment with E 2 versus those that will respond more slowly and less dramatically. We modeled these different scenarios with MCF-7:5C and MCF-7:2A cell lines, respectively.
We have found that the UPR, associated with endoplasmic reticulum stress (ERS), is a fundamental element in E 2 -induced MCF-7:5C cell apoptosis (8) . In this setting, E 2 triggers UPR and rapidly causes apoptosis within one week of treatment. Two main sensors of the UPR, IRE1α and PERK are activated in both cell lines similarly. PERK activation is confirmed by elevated p-eIF2α, since eIF2α is phosphorylated by activated PERK. In MCF-7:2A cells, the same sensors are activated as in MCF-7:5C cells (Fig. 3) , but significant cell death is not apparent at the same timepoint ( Fig. 2A) . Despite similar signaling patterns, the biological responses between the two cell lines differ. Our data suggested that another mechanism was preventing cell death after E 2 -induced UPR in MCF-7:2A cells.
Oxidative stress is a critical pathway for MCF-7:2A cells to undergo E 2 -induced apoptosis. MCF-7:2A cells inherently exhibit stronger survival and antioxidant mechanisms than MCF-7:5C cells (Figs. 4-6 ). This relationship is consistent with previously published data showing that MCF-7 cells with higher levels of glutathione peroxidase-1 (GSHPx-1) can survive better under oxidative stress conditions, such as hydrogen peroxide treatment (13) , and that MCF-7 cells can increase antioxidant enzymes (i.e. manganese superoxide dismutase, MnSOD) to prevent TNF-mediated apoptosis (14) . Activation of E 2 -induced apoptosis in MCF-7:2A cells also seems to require TNF family member upregulation ( Additionally, B cell lymphoma 2 (BCL2) plays a role in preventing cell death caused by oxidative stress (15) . In fact, MCF-7:2A cells exhibit 3.76-fold and 3.02-fold higher basal BCL2 and B cell lymphoma extra large (BCL-xL, BCL2L1) mRNA levels than MCF-7:5C cells, respectively (Table I) , providing support for the idea of a stronger survival signal.
Other data from our lab shows that MCF-7:2A cells exhibit 6.19-fold higher glutathione peroxidase 2 gene (GPX2) over MCF-7:5C cells (Table II) , illustrating more evidence in favor of increased protection from E 2 -induced oxidative stress and apoptosis in this context.
Increased IGFR promotes anti-hormone resistance in breast cancer, likely through growth factor receptor crosstalk and aberrant ER, MAPK, and AKT signal transduction pathway activation (16) (17) (18) . Our data correlate with these findings in that higher IGF-1Rβ mRNA and protein expression confer a growth advantage and apoptotic resistance in MCF-7:2A cells despite treatment with E 2 (Fig. 7) . This suggests an IGF-1Rβ signaling pathway that can circumvent normal ER signaling in long-term estrogen-deprived breast cancer cells. Studies using hepatocellular carcinoma cells (HCC) have demonstrated that IGF-1R overexpression can potentially cause increased glutathione transferase (GST) and protection from oxidative stress (19) . Although Prostaglandin-endoperoxide synthase 1
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this mechanism is shown in liver cancer cells, it may apply to our models of breast cancer as well. Perhaps the higher level of IGF-1Rβ in MCF-7:2A cells generates the increased glutathione levels necessary to escape cell death in the presence of E 2 .
The evidence thus far shows that TNF family member gene expression, protection against oxidative stress, and growth factor signaling are major mechanisms underlying the different biological responses to E 2 seen in MCF-7:2A cells versus MCF-7:5C cells. Despite similar UPR signaling patterns, MCF-7:2A cells resist ERS-induced death longer and stronger than MCF-7:5C cells. Additional studies may provide further insight into the connection between IGF-1Rβ and glutathione in MCF-7:2A cells, and how this relationship functions in the presence and absence of a stressor such as E 2 . In order to effectively treat breast cancer patients who have undergone exhaustive anti-hormone treatment, and to explain why ERT can prevent breast cancer in some post-menopausal women, the examination of breast cancer cell models of E 2 deprivation is proving invaluable. By understanding mechanisms that prevent apoptosis in these breast cancer cells, we can translate key findings into clinical practice.
